Eisai ups capacity for Alzheimer’s disease pills and PPIs in China

By Gareth Macdonald contact

- Last updated on GMT

Gettyimages/MarianVejcik
Gettyimages/MarianVejcik
Eisai Co Ltd has completed construction of an oral solid dose form manufacturing facility in Suzhou, China.

The Japanese drug firm announced completion of the project today, explaining the new facility has capacity to make three billion tablets a year. The site will be operational in the second half of the year.

Eisai has made medicines in Suzhou since 2014 when it set up a facility for the production of injectable Methycobal (mecobalamin), which is used to treat anaemia and nerve damage.

The newly completed plant will make and package an oral solid dosage form version of Methycobal.

It will also produce the Alzheimer’s disease pill Aricept (donepezil) and the proton pump inhibitor Pariet (rabeprazole sodium) for the Chinese market.

Eisai’s existing facility will close after the new plant is operational.

The firm said, “Through the completion of the OSD production facility at the new Suzhou Plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain​.”

China business

Eisai​ generated revenue of ¥49.2bn ($7.5bn) in China in the fiscal year ended March 31, 2017, up 17% year-on-year.

Methycobal revenue fell 4% to ¥17.9bn. Aricept brought in ¥6.1bn, which is an increase of 11.1%.

Related news

Show more

Related products

show more

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers

Follow us

Products

View more

Webinars